JAK2 inhibitors and their impact in myeloproliferative neoplasms

Holly L. Geyer, Raoul Tibes, Ruben A. Mesa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Historically, complex biochemical alterations defining these heterogeneously distinct malignancies have remained elusive and constrained available therapy options. The discovery of Janus kinase (JAK) mutations collectively present in BCR-ABL-negative MPNs has led to a resurgence of medical interest in JAK-STAT targeted treatment modalities, as well as provided a unique platform for inhibiting symptom-directing proinflammatory cytokines. INCB018424, CYT387, SB1518, and TG101348 are among the most propitious JAK2 inhibitors under investigation, providing substantial improvement in constitutional symptoms, transfusion-dependent cytopenias, and reduction in spleen size. Despite their attributes, evidence of complete or partial remission has yet to be observed with therapy. Many uncertainties surrounding the full clinical potential of JAK2 inhibitors persist. Treatment guidelines addressing optimal stages for drug implementation, ideal dosing parameters and criteria for medication continuation/withdrawal may effectively resolve these ongoing concerns and provide advancements in the morbidity and mortality of these multifaceted disease processes.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012

Fingerprint

Janus Kinases
Essential Thrombocythemia
Neoplasms
Polycythemia Vera
Primary Myelofibrosis
Uncertainty
Spleen
Guidelines
Cytokines
Morbidity
Mutation
Mortality
Therapeutics
Pharmaceutical Preparations
INCB018424
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
TG101348

Keywords

  • Acute leukemia
  • Essential thrombocythemia
  • JAK2 inhibitor
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Hematology

Cite this

JAK2 inhibitors and their impact in myeloproliferative neoplasms. / Geyer, Holly L.; Tibes, Raoul; Mesa, Ruben A.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

Geyer, Holly L. ; Tibes, Raoul ; Mesa, Ruben A. / JAK2 inhibitors and their impact in myeloproliferative neoplasms. In: Hematology. 2012 ; Vol. 17, No. SUPPL. 1.
@article{f14a3eeb4d904739b04ee19b4db05c2a,
title = "JAK2 inhibitors and their impact in myeloproliferative neoplasms",
abstract = "The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Historically, complex biochemical alterations defining these heterogeneously distinct malignancies have remained elusive and constrained available therapy options. The discovery of Janus kinase (JAK) mutations collectively present in BCR-ABL-negative MPNs has led to a resurgence of medical interest in JAK-STAT targeted treatment modalities, as well as provided a unique platform for inhibiting symptom-directing proinflammatory cytokines. INCB018424, CYT387, SB1518, and TG101348 are among the most propitious JAK2 inhibitors under investigation, providing substantial improvement in constitutional symptoms, transfusion-dependent cytopenias, and reduction in spleen size. Despite their attributes, evidence of complete or partial remission has yet to be observed with therapy. Many uncertainties surrounding the full clinical potential of JAK2 inhibitors persist. Treatment guidelines addressing optimal stages for drug implementation, ideal dosing parameters and criteria for medication continuation/withdrawal may effectively resolve these ongoing concerns and provide advancements in the morbidity and mortality of these multifaceted disease processes.",
keywords = "Acute leukemia, Essential thrombocythemia, JAK2 inhibitor, Myelofibrosis, Myeloproliferative neoplasms, Polycythemia vera, Primary myelofibrosis",
author = "Geyer, {Holly L.} and Raoul Tibes and Mesa, {Ruben A.}",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156375",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - JAK2 inhibitors and their impact in myeloproliferative neoplasms

AU - Geyer, Holly L.

AU - Tibes, Raoul

AU - Mesa, Ruben A.

PY - 2012/4

Y1 - 2012/4

N2 - The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Historically, complex biochemical alterations defining these heterogeneously distinct malignancies have remained elusive and constrained available therapy options. The discovery of Janus kinase (JAK) mutations collectively present in BCR-ABL-negative MPNs has led to a resurgence of medical interest in JAK-STAT targeted treatment modalities, as well as provided a unique platform for inhibiting symptom-directing proinflammatory cytokines. INCB018424, CYT387, SB1518, and TG101348 are among the most propitious JAK2 inhibitors under investigation, providing substantial improvement in constitutional symptoms, transfusion-dependent cytopenias, and reduction in spleen size. Despite their attributes, evidence of complete or partial remission has yet to be observed with therapy. Many uncertainties surrounding the full clinical potential of JAK2 inhibitors persist. Treatment guidelines addressing optimal stages for drug implementation, ideal dosing parameters and criteria for medication continuation/withdrawal may effectively resolve these ongoing concerns and provide advancements in the morbidity and mortality of these multifaceted disease processes.

AB - The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Historically, complex biochemical alterations defining these heterogeneously distinct malignancies have remained elusive and constrained available therapy options. The discovery of Janus kinase (JAK) mutations collectively present in BCR-ABL-negative MPNs has led to a resurgence of medical interest in JAK-STAT targeted treatment modalities, as well as provided a unique platform for inhibiting symptom-directing proinflammatory cytokines. INCB018424, CYT387, SB1518, and TG101348 are among the most propitious JAK2 inhibitors under investigation, providing substantial improvement in constitutional symptoms, transfusion-dependent cytopenias, and reduction in spleen size. Despite their attributes, evidence of complete or partial remission has yet to be observed with therapy. Many uncertainties surrounding the full clinical potential of JAK2 inhibitors persist. Treatment guidelines addressing optimal stages for drug implementation, ideal dosing parameters and criteria for medication continuation/withdrawal may effectively resolve these ongoing concerns and provide advancements in the morbidity and mortality of these multifaceted disease processes.

KW - Acute leukemia

KW - Essential thrombocythemia

KW - JAK2 inhibitor

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Polycythemia vera

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84859766271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859766271&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156375

DO - 10.1179/102453312X13336169156375

M3 - Article

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -